DK1789433T3 - Fremgangsmåder til at behandle kutan rødmen med selektive alfa-2-adrenerge receptoragonister - Google Patents

Fremgangsmåder til at behandle kutan rødmen med selektive alfa-2-adrenerge receptoragonister

Info

Publication number
DK1789433T3
DK1789433T3 DK04778941T DK04778941T DK1789433T3 DK 1789433 T3 DK1789433 T3 DK 1789433T3 DK 04778941 T DK04778941 T DK 04778941T DK 04778941 T DK04778941 T DK 04778941T DK 1789433 T3 DK1789433 T3 DK 1789433T3
Authority
DK
Denmark
Prior art keywords
methods
receptor agonists
adrenergic receptor
selective alpha
treating cutaneous
Prior art date
Application number
DK04778941T
Other languages
English (en)
Inventor
Warren J Scherer
Original Assignee
Galderma Pharma Sa
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Galderma Pharma Sa filed Critical Galderma Pharma Sa
Application granted granted Critical
Publication of DK1789433T3 publication Critical patent/DK1789433T3/da

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0014—Skin, i.e. galenical aspects of topical compositions
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/185—Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic or hydroximic acids
    • A61K31/19—Carboxylic acids, e.g. valproic acid
    • A61K31/194—Carboxylic acids, e.g. valproic acid having two or more carboxyl groups, e.g. succinic, maleic or phthalic acid
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/498—Pyrazines or piperazines ortho- and peri-condensed with carbocyclic ring systems, e.g. quinoxaline, phenazine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P5/00—Drugs for disorders of the endocrine system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P5/00—Drugs for disorders of the endocrine system
    • A61P5/24—Drugs for disorders of the endocrine system of the sex hormones

Landscapes

  • Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Animal Behavior & Ethology (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Medicinal Chemistry (AREA)
  • Epidemiology (AREA)
  • Dermatology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • General Chemical & Material Sciences (AREA)
  • Endocrinology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Engineering & Computer Science (AREA)
  • Diabetes (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
DK04778941T 2003-07-23 2004-07-21 Fremgangsmåder til at behandle kutan rødmen med selektive alfa-2-adrenerge receptoragonister DK1789433T3 (da)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US10/626,037 US20050020600A1 (en) 2003-07-23 2003-07-23 Methods of treating cutaneous flushing using selective alpha-2-adrenergic receptor agonists
PCT/US2004/023649 WO2005010025A2 (en) 2003-07-23 2004-07-21 Methods of treating cutaneous flushing using selective alpha-2-adrenergic receptor agonists

Publications (1)

Publication Number Publication Date
DK1789433T3 true DK1789433T3 (da) 2012-09-17

Family

ID=34080324

Family Applications (1)

Application Number Title Priority Date Filing Date
DK04778941T DK1789433T3 (da) 2003-07-23 2004-07-21 Fremgangsmåder til at behandle kutan rødmen med selektive alfa-2-adrenerge receptoragonister

Country Status (9)

Country Link
US (2) US20050020600A1 (da)
EP (2) EP1789433B1 (da)
CY (1) CY1113055T1 (da)
DK (1) DK1789433T3 (da)
ES (1) ES2386786T3 (da)
PL (1) PL1789433T3 (da)
PT (1) PT1789433E (da)
SI (1) SI1789433T1 (da)
WO (1) WO2005010025A2 (da)

Families Citing this family (43)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DE10013318A1 (de) * 2000-03-17 2001-09-20 Merck Patent Gmbh Formulierung enthaltend Chinoxalinderivate
IL147921A0 (en) * 2002-01-31 2002-08-14 Abdulrazik Mohammad A method for treating central nervous system disorders by ocular dosing
US20040266776A1 (en) 2003-06-25 2004-12-30 Gil Daniel W. Methods of preventing and reducing the severity of stress-associated conditions
US8410102B2 (en) 2003-05-27 2013-04-02 Galderma Laboratories Inc. Methods and compositions for treating or preventing erythema
US7439241B2 (en) 2003-05-27 2008-10-21 Galderma Laboratories, Inc. Compounds, formulations, and methods for treating or preventing rosacea
US7812049B2 (en) * 2004-01-22 2010-10-12 Vicept Therapeutics, Inc. Method and therapeutic/cosmetic topical compositions for the treatment of rosacea and skin erythema using α1-adrenoceptor agonists
ES2424644T3 (es) * 2004-05-25 2013-10-07 Galderma Pharma S.A. Compuestos, formulaciones y métodos para tratar o prevenir los trastornos inflamatorios de la piel
GB0611241D0 (en) * 2006-06-07 2006-07-19 Daniolabs Ltd The treatment of increased sebum production
WO2009017705A1 (en) * 2007-07-27 2009-02-05 Galderma Laboratories L.P. Compounds, formulations, and methods for reducing skin wrinkles, creasing and sagging
US20090061020A1 (en) * 2007-08-31 2009-03-05 Theobald Klaus P Brimonidine Compositions for Treating Erythema
KR100916716B1 (ko) * 2007-09-27 2009-09-10 한국화학연구원 3-클로로-5-치환-퀴녹살린-2-아민 유도체 및 약제학적으로허용 가능한 그의 염, 그의 제조방법 및 그를 유효성분으로함유하는 ｓｐｃ 수용체 활성으로 유발되는 염증관련 질환치료제
PT2818184T (pt) * 2007-11-16 2019-01-28 Aclaris Therapeutics Inc Composições e métodos para o tratamento de púrpura
US20110003823A1 (en) * 2008-08-01 2011-01-06 Alpha Synergy Development, Inc. Compositions and methods for treatment of diseases and conditions associated with vasodilation and/or vascular leakage
US12246013B2 (en) 2008-08-01 2025-03-11 Eye Therapies Llc Vasoconstriction compositions and methods of use
US8952011B2 (en) 2008-08-01 2015-02-10 Eye Therapies Llc Compositions and methods for the treatment of nasal conditions
US20100202979A1 (en) * 2008-08-01 2010-08-12 Gerald Horn Compositions and methods for treatment of pulmonary diseases and conditions
US20100028266A1 (en) * 2008-08-01 2010-02-04 Alpha Synergy Development. Inc. Composition and methods for treating allergic response
US20100197694A1 (en) * 2008-08-01 2010-08-05 Gerald Horn Compositions and methods for treatment of diseases and conditions with increased vascular permeability
US20100203165A1 (en) 2008-08-01 2010-08-12 Gerald Horn Compositions and methods for treatment of disorders or conditions of the eye
FR2942138A1 (fr) * 2009-02-16 2010-08-20 Galderma Res & Dev Association de composes pour le traitement ou la prevention des affections dermatologiques
US8987270B2 (en) 2009-07-27 2015-03-24 Eye Therapies Llc Formulations of selective alpha-2 agonists and methods of use thereof
MX2012004890A (es) * 2009-10-26 2012-09-28 Galderma Pharma Sa Metodos para tratar o prevenir eritema agudo.
EP2329849B1 (en) 2009-11-18 2015-04-29 Galderma Research & Development Combination of alpha-2 adrenergic receptor agonist and non-steroidal anti-inflammatory agent for treating or preventing an inflammatory skin disorder
US8394800B2 (en) * 2009-11-19 2013-03-12 Galderma Laboratories, L.P. Method for treating psoriasis
CN103298472A (zh) 2010-03-26 2013-09-11 盖尔德马研究及发展公司 安全和有效治疗红斑的改进的方法和组合物
WO2011117378A2 (en) 2010-03-26 2011-09-29 Galderma Research & Development Improved methods and compositions for safe and effective treatment of telangiectasia
AU2011273509A1 (en) * 2010-06-30 2013-06-13 Galderma Research & Development Use of alpha-adrenergic receptor agonist for preventing or treating skin tumor
RU2587041C2 (ru) * 2010-06-30 2016-06-10 Галдерма Ресерч Энд Девелопмент Способ предотвращения или лечения опухоли кожи
AU2011287544B2 (en) 2010-08-06 2014-12-11 Galderma Research & Development Combination of compounds for treating or preventing skin diseases
US8053427B1 (en) 2010-10-21 2011-11-08 Galderma R&D SNC Brimonidine gel composition
ES2498217T5 (es) 2010-10-21 2018-03-19 Galderma S.A. Composición en forma de gel basada en brimonidina
RU2013123043A (ru) 2010-10-21 2014-12-10 Галдерма С.А. Гелевая композиция для местного применения
WO2013016072A1 (en) * 2011-07-22 2013-01-31 Allergan, Inc. Pharmaceutical compositions comprising 4-bromo-n-(imidazolidin-2-ylidene)-1h-benzimidazol-5-amine for treating skin diseases
WO2013057579A2 (en) * 2011-10-19 2013-04-25 Galderma Pharma S.A. Method of reducing facial flushing associated with systemic use of phosphodiesterase type 5 inhibitors
UA109359C2 (xx) * 2011-11-10 2015-08-10 Лікування захворювань і станів шкіри 7-(1h-імідазол-4-ілметил)-5,6,7,8-тетрагідрохіноліном
US9283217B2 (en) 2011-11-10 2016-03-15 Allergan, Inc. Pharmaceutical compositions comprising 7-(1 H-imidazol-4-ylmethyl)-5,6,7,8-tetrahydro-quinoline for treating skin diseases and conditions
FR3000397A1 (fr) 2012-12-31 2014-07-04 Galderma Res & Dev Combinaison de laropiprant et d'ivermectine pour le traitement de la rosacee
RU2646512C2 (ru) 2013-10-07 2018-03-05 ТЕЙКОКУ ФАРМА ЮЭсЭй, ИНК. Устройства для трансдермальной доставки дексмедетомидина и способы их применения
KR101891185B1 (ko) 2013-10-07 2018-08-24 테이코쿠 팔마 유에스에이, 인코포레이티드 비진정량의 덱스메데토미딘의 경피 전달을 위한 방법 및 조성물
TWI709417B (zh) 2013-10-07 2020-11-11 美商帝國製藥美國股份有限公司 使用右美托咪啶經皮組成物用於治療注意力不足過動症、焦慮及失眠的方法及組成物
FR3015288B1 (fr) 2013-12-19 2016-02-12 Galderma Res & Dev Utilsation du naratriptan dans le traitement de la rosacee
KR20190060007A (ko) 2016-10-31 2019-05-31 테이코쿠 팔마 유에스에이, 인코포레이티드 덱스메데토미딘 경피 전달 장치를 이용한 통증을 관리하는 방법
KR20220002950A (ko) 2019-05-01 2022-01-07 클렉시오 바이오사이언시스 리미티드 소양증의 치료 방법

Family Cites Families (24)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US3674027A (en) * 1969-08-06 1972-07-04 Raul Fleischmajer Disposable wet compresses
US4029792A (en) 1972-02-29 1977-06-14 Pfizer Inc. (2-Imidazolin-2-ylamino) substituted -quinoxalines and -quinazolines as antihypertensive agents
US4201211A (en) 1977-07-12 1980-05-06 Alza Corporation Therapeutic system for administering clonidine transdermally
US4285967A (en) * 1978-06-30 1981-08-25 Estee Lauder Inc. Cosmetic preparation for reducing redness of blemishes
US4256763A (en) * 1978-09-19 1981-03-17 Mchugh John E Treatment of herpes simplex infections and acne
US4315033A (en) * 1981-01-22 1982-02-09 Lawrason F Douglas Method of treating menopausal symptoms
US4800209A (en) * 1981-12-14 1989-01-24 Merrell Dow Pharmaceuticals Inc. Method of alleviating withdrawal symptoms
US4661476A (en) * 1985-04-08 1987-04-28 Plough, Inc. Skin cooling method
WO1993025177A1 (en) * 1992-06-17 1993-12-23 The Procter & Gamble Company Coolant compositions with reduced stinging
US5527530A (en) * 1994-07-08 1996-06-18 The Procter & Gamble Company Alcoholic moisturizing after shave lotion
US5525344A (en) * 1995-01-03 1996-06-11 Chesebrough-Pond's Usa Co., Division Of Conopco, Inc. Clear cold cream cosmetic compositions
US5643586A (en) * 1995-04-27 1997-07-01 Perricone; Nicholas V. Topical compositions and methods for treatment of skin damage and aging using catecholamines and related compounds
US6194415B1 (en) 1995-06-28 2001-02-27 Allergan Sales, Inc. Method of using (2-imidazolin-2-ylamino) quinoxoalines in treating neural injury
US5916574A (en) * 1996-10-09 1999-06-29 Ideal Ideas, Inc. Method of treating natural poison skin conditions
WO1998036730A2 (de) 1997-02-21 1998-08-27 Beiersdorf Ag Zubereitungen für die behandlung von rosacea
ATE271048T1 (de) * 1997-11-24 2004-07-15 Procter & Gamble 5-(2-imidazolinylamino)-benzimidazol derivate, deren herstellung und deren verwendung als .alpha.-adrenoceptor agonisten mit verbesserter metabolischer stabilität
US5962505A (en) * 1998-08-31 1999-10-05 Bobrove; Arthur M. Method for treating hot flashes in humans
US6147102A (en) 1999-10-26 2000-11-14 Curatek Pharmaceuticals Holding, Inc. Clonidine preparations
US6680062B2 (en) 2001-10-05 2004-01-20 Color Access, Inc. Anti-irritating rosacea treatment
US20040266776A1 (en) * 2003-06-25 2004-12-30 Gil Daniel W. Methods of preventing and reducing the severity of stress-associated conditions
US20040156873A1 (en) * 2003-02-10 2004-08-12 Gupta Shyam K. Topically Bioavailable Acne and Rosacea Treatment Compositions
US7439241B2 (en) * 2003-05-27 2008-10-21 Galderma Laboratories, Inc. Compounds, formulations, and methods for treating or preventing rosacea
US7812049B2 (en) * 2004-01-22 2010-10-12 Vicept Therapeutics, Inc. Method and therapeutic/cosmetic topical compositions for the treatment of rosacea and skin erythema using α1-adrenoceptor agonists
ES2424644T3 (es) * 2004-05-25 2013-10-07 Galderma Pharma S.A. Compuestos, formulaciones y métodos para tratar o prevenir los trastornos inflamatorios de la piel

Also Published As

Publication number Publication date
HK1104308A1 (en) 2008-01-11
US20150031700A1 (en) 2015-01-29
PT1789433E (pt) 2012-07-24
CY1113055T1 (el) 2016-04-13
WO2005010025A2 (en) 2005-02-03
ES2386786T3 (es) 2012-08-30
EP2481747A1 (en) 2012-08-01
WO2005010025A3 (en) 2006-03-23
EP1789433A4 (en) 2010-08-18
SI1789433T1 (sl) 2012-09-28
EP1789433A2 (en) 2007-05-30
PL1789433T3 (pl) 2012-10-31
US20050020600A1 (en) 2005-01-27
EP1789433B1 (en) 2012-06-06

Similar Documents

Publication Publication Date Title
SI1789433T1 (sl) Postopki za zdravljenje kutane rdečice ob uporabi selektivnih alfa-2-adrenergičnih receptorskih agonistov
EP1696877A4 (en) PROCESS FOR PAIN TREATMENT
EP1736763A4 (en) ANALISEUR
DK1718641T3 (da) Benzimidazolderivat og dets anvendelse som All-receptorantagonist
DK1677623T3 (da) Tyggeemne til kæledyr
ITRM20030451A1 (it) Metodo e dispositivo per la rivelazione e la
ATE341543T1 (de) Pyridinoylpiperidine als 5-ht1f agonisten
DE602004011316D1 (de) Wälzlager Vorrichtung
DK1692102T3 (da) Sammensætninger og fremgangsmåder til at påvise og behandle sygdomme og tilstande knyttet til chemokinreceptorer
FI20030921L (fi) Monikanavainen testiväline, menetelmä sen valmistamiseksi ja sen käyttö
FI20045467L (fi) Menetelmä putkiporaukseen, porausyksikkö sekä adapterilaite
DE602005015929D1 (de) Beobachtungsgerät
NO20043366L (no) Kortikotropinfrigjorende faktor-2 reseptoragonister
AR028579A1 (es) Metodo para el tratamiento de la sequedad vaginal, con agonistas del receptor de acetilcolina nicotinica
DE112004000860D2 (de) Gating-Verfahren, Gating-Gerät, sowie Therapieeinrichtung
DK1703965T3 (da) Indretning, fremgangsmåde og anvendelse til at danne små partikler
FI20045103L (fi) Putken katkaisulaite
DE102005043175B8 (de) Zylindervorrichtung
NO20043240L (no) Fremgangsmate for behandling av seksuelle dysfunksjoner med delta-opioidreseptoragonistforbindelse
DK1692915T3 (da) Kommunikationsanordning med strukturdel
DE602005002717D1 (de) Vorrichtung zum Angeln
DK1622892T3 (da) Indazoler med analgetisk aktivitet
DE112005002114A5 (de) Vorrichtung zum elektrochemischen Schneiden
PT1749090T (pt) Formulação, método e composição para terapia celular
FI20030173L (fi) Laite jatkuvatoimiseen lietenäytteen laimentamiseen